Johnson & Johnson’s Joaquin Duato is no longer the highest paid CEO in pharma. Meanwhile, just two women make the top 10.

Key Takeaways A pill to treat obesity caused liver injury in a clinical trialPfizer said it will stop developing the drug, called danuglipron, as a result Other alternatives to injectable obesity ...

Medications like Ozempic, Wegovy, and Zepbound have helped many Americans lose weight, but there are still some ...

People who have tried other methods to lose weight have found results from obesity drugs that ‘feel like magic.’ ...

Pfizer had intended to move the drug into late-stage testing, but called it quits after a patient in a clinical trial ...

Pfizer is ending the development of its potential once-daily pill treatment for obesity before venturing into the biggest and ...

The drug manufacturer will no longer study and test danuglipron after a participant in a clinical trial was injured.

A study found that medicines marketed as Zepbound and Mounjaro can help people lose weight for up to three years.

The India launch of Eli Lilly's popular weight-loss drug Mounjaro has triggered a huge wave of patient enquiries about its ...

Pfizer’s announcement that it will stop developing its oral weight-loss drug gave shares of Wegovy maker Novo Nordisk and ...

Ryan Rasmussen was determined to lose weight so he would be around to ski and spend time with his wife and children.